Characterization of a host hepatocyte factor that regulates HCV replication

调节 HCV 复制的宿主肝细胞因子的表征

基本信息

  • 批准号:
    8296579
  • 负责人:
  • 金额:
    $ 13.23万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-06-15 至 2013-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Chronic hepatitis C virus (HCV) infection develops in 70-80% of all exposed individuals and affects 3% of the world's population. There is a need for more effective and better-tolerated HCV therapies. Our long-term goals are to define host-HCV molecular interactions and in so doing, to identify novel therapeutic agents for HCV therapy. We have completed a functional genomic screen for host cofactors for HCV replication using a whole- genome siRNA library. Among the many novel host cofactors identified is PI4KA, a phosphatidylinositol 4- kinase (PI 4-kinase). We hypothesize that PI4KA is necessary for formation of the altered host membranes required for HCV replication. This proposal describes a 5 year mentored training program to acquire further technical skills in the fields of molecular virology, phosphoinositides and cell trafficking, and cell imaging. These skills will be used to develop novel model systems to study the formation and composition of the HCV replication complex and its associated host membranes and proteins. The specific aims of this project are (1) to characterize the specificity of PI4KA inhibition for suppression of HCV replication, (2) to characterize the role of PI4KA through the viral replication cycle, and (3) to develop systems to study HCV replication complex assembly and composition. Although the specific aims are directed towards PI4KA, the systems and techniques to be developed during the award period will be applied to the study of other host cofactors of HCV replication. The proposed research will have direct public health benefits as a better understanding of the mechanisms that underline HCV replication complex assembly may lead to novel targets for HCV therapies. A better understanding of the HCV-host relationship is a stated goal of the NIH Action Plan for Liver Disease Research (Goal B2a). We have recently performed a whole-genome screen for human (host) proteins that are required by the hepatitis C virus for its replication. Such proteins are potential targets for new therapies for HCV. This proposal describes a 5-year research plan focusing on developing new systems to study how host cofactors direct the assembly of HCV replication complexes.
描述(由申请人提供): 70-80% 的接触者患有慢性丙型肝炎病毒 (HCV) 感染,影响世界人口的 3%。需要更有效和更好耐受的HCV疗法。我们的长期目标是确定宿主-HCV 分子相互作用,并在此过程中确定用于 HCV 治疗的新型治疗药物。我们已经使用全基因组 siRNA 文库完成了 HCV 复制宿主辅助因子的功能基因组筛选。在众多已鉴定的新型宿主辅助因子中,PI4KA 是一种磷脂酰肌醇 4-激酶(PI 4-激酶)。我们假设 PI4KA 对于 HCV 复制所需的改变的宿主膜的形成是必需的。该提案描述了一项为期 5 年的指导培训计划,旨在获得分子病毒学、磷酸肌醇和细胞运输以及细胞成像领域的进一步技术技能。这些技能将用于开发新的模型系统,以研究 HCV 复制复合物及其相关宿主膜和蛋白质的形成和组成。该项目的具体目标是 (1) 表征 PI4KA 抑制对抑制 HCV 复制的特异性,(2) 表征 PI4KA 在病毒复制周期中的作用,以及 (3) 开发系统来研究 HCV 复制复合物组装和组成。尽管具体目标是针对 PI4KA,但奖励期间开发的系统和技术将应用于 HCV 复制的其他宿主辅助因子的研究。拟议的研究将具有直接的公共健康益处,因为更好地了解 HCV 复制复合体组装的机制可能会导致 HCV 治疗的新靶点。更好地了解 HCV-宿主关系是 NIH 肝病研究行动计划(目标 B2a)的既定目标。我们最近对丙型肝炎病毒复制所需的人类(宿主)蛋白质进行了全基因组筛选。这些蛋白质是丙型肝炎新疗法的潜在靶点。该提案描述了一项为期 5 年的研究计划,重点是开发新系统来研究宿主辅助因子如何指导 HCV 复制复合物的组装。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A homogeneous and nonisotopic assay for phosphatidylinositol 4-kinases.
  • DOI:
    10.1016/j.ab.2011.05.046
  • 发表时间:
    2011-10-01
  • 期刊:
  • 影响因子:
    2.9
  • 作者:
    Tai AW;Bojjireddy N;Balla T
  • 通讯作者:
    Balla T
Genetic and functional studies of phosphatidyl-inositol 4-kinase type IIIα.
磷脂酰肌醇4激酶IIIα型的遗传和功能研究。
  • DOI:
    10.1016/j.bbalip.2011.04.013
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Szentpetery,Zsofia;Szakacs,Gergely;Bojjireddy,Naveen;Tai,AndrewW;Balla,Tamas
  • 通讯作者:
    Balla,Tamas
Oxysterol-binding protein is a phosphatidylinositol 4-kinase effector required for HCV replication membrane integrity and cholesterol trafficking.
  • DOI:
    10.1053/j.gastro.2014.02.002
  • 发表时间:
    2014-05
  • 期刊:
  • 影响因子:
    29.4
  • 作者:
    Wang H;Perry JW;Lauring AS;Neddermann P;De Francesco R;Tai AW
  • 通讯作者:
    Tai AW
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Andrew W. Tai其他文献

How to Effectively Engage With Preclinical Medical Learners
  • DOI:
    10.1053/j.gastro.2023.05.014
  • 发表时间:
    2023-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Andrew W. Tai;Justin L. Sewell
  • 通讯作者:
    Justin L. Sewell
Nivolumab-induced large-duct cholangiopathy treated with ursodeoxycholic acid and tocilizumab.
用熊去氧胆酸和托珠单抗治疗纳武单抗诱导的大管胆管病。
  • DOI:
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    2.8
  • 作者:
    C. Reddy;B. Schneider;Lindsay M Brackett;Andrew W. Tai
  • 通讯作者:
    Andrew W. Tai
High-Content Screening to Identify Inhibitors of Dengue Virus Replication
高内涵筛选识别登革热病毒复制抑制剂
  • DOI:
    10.1101/2023.03.24.534108
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Jillian G. Hoffstadt;J. W. Wotring;Sam Porter;B. Halligan;Matthew J. O’Meara;Andrew W. Tai;J. Sexton
  • 通讯作者:
    J. Sexton

Andrew W. Tai的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Andrew W. Tai', 18)}}的其他基金

How flaviviruses hijack a host transmembrane protein chaperone to promote viral infection
黄病毒如何劫持宿主跨膜蛋白伴侣以促进病毒感染
  • 批准号:
    10292571
  • 财政年份:
    2021
  • 资助金额:
    $ 13.23万
  • 项目类别:
How flaviviruses hijack a host transmembrane protein chaperone to promote viral infection
黄病毒如何劫持宿主跨膜蛋白伴侣以促进病毒感染
  • 批准号:
    10490440
  • 财政年份:
    2021
  • 资助金额:
    $ 13.23万
  • 项目类别:
How flaviviruses hijack a host transmembrane protein chaperone to promote viral infection
黄病毒如何劫持宿主跨膜蛋白伴侣以促进病毒感染
  • 批准号:
    10669214
  • 财政年份:
    2021
  • 资助金额:
    $ 13.23万
  • 项目类别:
Subversion of hepatocyte phosphoinositide metabolism by hepatitis C virus
丙型肝炎病毒破坏肝细胞磷酸肌醇代谢
  • 批准号:
    9241378
  • 财政年份:
    2013
  • 资助金额:
    $ 13.23万
  • 项目类别:
Subversion of hepatocyte phosphoinositide metabolism by hepatitis C virus
丙型肝炎病毒破坏肝细胞磷酸肌醇代谢
  • 批准号:
    8634774
  • 财政年份:
    2013
  • 资助金额:
    $ 13.23万
  • 项目类别:
Subversion of hepatocyte phosphoinositide metabolism by hepatitis C virus
丙型肝炎病毒破坏肝细胞磷酸肌醇代谢
  • 批准号:
    9029323
  • 财政年份:
    2013
  • 资助金额:
    $ 13.23万
  • 项目类别:
Subversion of hepatocyte phosphoinositide metabolism by hepatitis C virus
丙型肝炎病毒破坏肝细胞磷酸肌醇代谢
  • 批准号:
    8417277
  • 财政年份:
    2013
  • 资助金额:
    $ 13.23万
  • 项目类别:
Subversion of hepatocyte phosphoinositide metabolism by hepatitis C virus
丙型肝炎病毒破坏肝细胞磷酸肌醇代谢
  • 批准号:
    8826108
  • 财政年份:
    2013
  • 资助金额:
    $ 13.23万
  • 项目类别:
Characterization of a host hepatocyte factor that regulates HCV replication
调节 HCV 复制的宿主肝细胞因子的表征
  • 批准号:
    8082731
  • 财政年份:
    2010
  • 资助金额:
    $ 13.23万
  • 项目类别:
Characterization of a host hepatocyte factor that regulates HCV replication
调节 HCV 复制的宿主肝细胞因子的表征
  • 批准号:
    7989665
  • 财政年份:
    2010
  • 资助金额:
    $ 13.23万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 13.23万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 13.23万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 13.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 13.23万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 13.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 13.23万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 13.23万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 13.23万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 13.23万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 13.23万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了